Suppr超能文献

决定抗体在肿瘤中分布的因素。

Factors determining antibody distribution in tumors.

作者信息

Thurber Greg M, Schmidt Michael M, Wittrup K Dane

机构信息

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

出版信息

Trends Pharmacol Sci. 2008 Feb;29(2):57-61. doi: 10.1016/j.tips.2007.11.004. Epub 2008 Jan 7.

Abstract

The development of antibody therapies for cancer is increasing rapidly, primarily owing to their specificity. Antibody distribution in tumors is often extremely uneven, however, leading to some malignant cells being exposed to saturating concentrations of antibody, whereas others are completely untargeted. This is detrimental because large regions of cells escape therapy, whereas other regions might be exposed to suboptimal concentrations that promote a selection of resistant mutants. The distribution of antibody depends on a variety of factors, including dose, affinity, antigens per cell and molecular size. Because these parameters are often known or easily estimated, a quick calculation based on simple modeling considerations can predict the uniformity of targeting within a tumor. Such analyses should enable experimental researchers to identify in a straightforward way the limitations in achieving evenly distributed antibody, and design and test improved antibody therapeutics more rationally.

摘要

癌症抗体疗法的发展正在迅速增加,这主要归功于它们的特异性。然而,抗体在肿瘤中的分布往往极不均匀,导致一些恶性细胞暴露于饱和浓度的抗体中,而其他细胞则完全未被靶向。这是有害的,因为大量细胞区域逃避了治疗,而其他区域可能暴露于促进耐药突变体选择的次优浓度。抗体的分布取决于多种因素,包括剂量、亲和力、每个细胞的抗原和分子大小。由于这些参数通常是已知的或易于估计的,基于简单建模考虑的快速计算可以预测肿瘤内靶向的均匀性。此类分析应能使实验研究人员以直接的方式识别在实现抗体均匀分布方面的局限性,并更合理地设计和测试改进的抗体疗法。

相似文献

1
Factors determining antibody distribution in tumors.决定抗体在肿瘤中分布的因素。
Trends Pharmacol Sci. 2008 Feb;29(2):57-61. doi: 10.1016/j.tips.2007.11.004. Epub 2008 Jan 7.
2
Coming-of-Age of Antibodies in Cancer Therapeutics.抗体在癌症治疗中的成熟之路。
Trends Pharmacol Sci. 2016 Dec;37(12):1009-1028. doi: 10.1016/j.tips.2016.09.005. Epub 2016 Oct 10.
3
Cancer drug targeting.癌症药物靶向治疗
Clin Radiol. 1985 Nov;36(6):545-51. doi: 10.1016/s0009-9260(85)80230-0.

引用本文的文献

5
Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.用于癌症治疗的肿瘤归巢抗体-细胞因子融合物
Onco Targets Ther. 2024 Aug 29;17:697-715. doi: 10.2147/OTT.S480787. eCollection 2024.
10
Hyperstable Synthetic Mini-Proteins as Effective Ligand Scaffolds.超稳定合成微型蛋白作为有效的配体支架
ACS Synth Biol. 2023 Dec 15;12(12):3608-3622. doi: 10.1021/acssynbio.3c00409. Epub 2023 Nov 27.

本文引用的文献

5
Drug penetration in solid tumours.药物在实体瘤中的渗透。
Nat Rev Cancer. 2006 Aug;6(8):583-92. doi: 10.1038/nrc1893.
7
Monoclonal antibody therapy of cancer.癌症的单克隆抗体疗法。
Nat Biotechnol. 2005 Sep;23(9):1147-57. doi: 10.1038/nbt1137.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验